These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 36073793)

  • 1. Spatial- and Valence-Matched Neutralizing DNA Nanostructure Blocks Wild-Type SARS-CoV-2 and Omicron Variant Infection.
    Wan S; Liu S; Sun M; Zhang J; Wei X; Song T; Li Y; Liu X; Chen H; Yang CJ; Song Y
    ACS Nano; 2022 Sep; 16(9):15310-15317. PubMed ID: 36073793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatially Patterned Neutralizing Icosahedral DNA Nanocage for Efficient SARS-CoV-2 Blocking.
    Zhang J; Xu Y; Huang Y; Sun M; Liu S; Wan S; Chen H; Yang C; Yang Y; Song Y
    J Am Chem Soc; 2022 Jul; 144(29):13146-13153. PubMed ID: 35770902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.
    Mercurio I; Tragni V; Busto F; De Grassi A; Pierri CL
    Cell Mol Life Sci; 2021 Feb; 78(4):1501-1522. PubMed ID: 32623480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced Binding between Omicron B.1.1.529 and the Human ACE2 Receptor in a Surrogate Virus Neutralization Test for SARS-CoV-2.
    Hoffman T; Kolstad L; Akaberi D; Järhult JD; Rönnberg B; Lundkvist Å
    Viruses; 2023 May; 15(6):. PubMed ID: 37376580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron BA.2 variant compared to BA.1 and their possible mouse origins.
    Xu Y; Wu C; Cao X; Gu C; Liu H; Jiang M; Wang X; Yuan Q; Wu K; Liu J; Wang D; He X; Wang X; Deng SJ; Xu HE; Yin W
    Cell Res; 2022 Jul; 32(7):609-620. PubMed ID: 35641567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly efficacious and safe neutralizing DNA aptamer of SARS-CoV-2 as an emerging therapy for COVID-19 disease.
    Ayass MA; Tripathi T; Griko N; Pashkov V; Dai J; Zhang J; Herbert FC; Ramankutty Nair R; Okyay T; Zhu K; Gassensmith JJ; Abi-Mosleh L
    Virol J; 2022 Dec; 19(1):227. PubMed ID: 36581924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Glycosylation and Disulfide Bonding of Wild-Type SARS-CoV-2 Spike Glycoprotein.
    Zhang S; Go EP; Ding H; Anang S; Kappes JC; Desaire H; Sodroski JG
    J Virol; 2022 Feb; 96(3):e0162621. PubMed ID: 34817202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein.
    Javanmardi K; Segall-Shapiro TH; Chou CW; Boutz DR; Olsen RJ; Xie X; Xia H; Shi PY; Johnson CD; Annapareddy A; Weaver S; Musser JM; Ellington AD; Finkelstein IJ; Gollihar JD
    Cell Host Microbe; 2022 Sep; 30(9):1242-1254.e6. PubMed ID: 35988543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
    Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
    Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
    Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
    Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Spike Antibody Response to Natural Infection with SARS-CoV-2 and Its Activity against Emerging Variants.
    Chen CP; Huang KA; Shih SR; Lin YC; Cheng CY; Huang YC; Lin TY; Cheng SH
    Microbiol Spectr; 2022 Aug; 10(4):e0074322. PubMed ID: 35703556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody.
    Yin W; Xu Y; Xu P; Cao X; Wu C; Gu C; He X; Wang X; Huang S; Yuan Q; Wu K; Hu W; Huang Z; Liu J; Wang Z; Jia F; Xia K; Liu P; Wang X; Song B; Zheng J; Jiang H; Cheng X; Jiang Y; Deng SJ; Xu HE
    Science; 2022 Mar; 375(6584):1048-1053. PubMed ID: 35133176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 spike protein variant binding affinity to an angiotensin-converting enzyme 2 fusion glycoproteins.
    Matthews AM; Biel TG; Ortega-Rodriguez U; Falkowski VM; Bush X; Faison T; Xie H; Agarabi C; Rao VA; Ju T
    PLoS One; 2022; 17(12):e0278294. PubMed ID: 36472974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells.
    Appelberg S; Ahlén G; Yan J; Nikouyan N; Weber S; Larsson O; Höglund U; Aleman S; Weber F; Perlhamre E; Apro J; Gidlund EK; Tuvesson O; Salati S; Cadossi M; Tegel H; Hober S; Frelin L; Mirazimi A; Sällberg M
    EMBO Mol Med; 2022 Oct; 14(10):e15821. PubMed ID: 35986481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structures of Omicron spike complexes and implications for neutralizing antibody development.
    Guo H; Gao Y; Li T; Li T; Lu Y; Zheng L; Liu Y; Yang T; Luo F; Song S; Wang W; Yang X; Nguyen HC; Zhang H; Huang A; Jin A; Yang H; Rao Z; Ji X
    Cell Rep; 2022 May; 39(5):110770. PubMed ID: 35477022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.